Dan Costin is an Oncology physician affiliated with White Plains Hospital. OpenAlex indexes 25 publications with 692 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2 Longview Ave
Ste. 201
White Plains, NY 106015002
Telephone
914-684-2779Registry record last updated 12 Jan 2017.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20251 payment
- Amgen Inc.Program year20232 payments
- ARRAY BIOPHARMA INCProgram year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
37%Aromatase Inhibitor16.8%Anastrozole67%Letrozole33%Part D<11 patientsKinase inhibitor7.9%Lenvima57%Ibrance43%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
19.7%Potassium supplement7.6%Potassium Chloride100%Part D<11 patientsCorticosteroid6.3%Prednisone100%Part D≥12 patients+ 2 more classes in this area
Cardiovascular
15.2%Calcium channel blocker5.8%Amlodipine Besylate100%Part D<11 patientsStatin5%Atorvastatin Calcium100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1993–1994 per NIH RePORTER. The latest:
- CLINICAL TRIAL OF ISOBUTYRAMIDE IN BETA THALASSEMIA AND SICKLE CELL ANEMIA
New York University
FY1994M01RR000096 - CLINICAL TRIAL OF ISOBUTYRAMIDE IN BETA THALASSEMIA AND SICKLE CELL ANEMIA
New York University
FY1993M01RR000096
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Transient Serpentine Supravenous Erythema During Rapid Drug Desensitization
The Journal of Allergy and Clinical Immunology In Practice
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Alan Multz, MD
White Plains Hospital
Daniel Sammartino
White Plains Hospital
Virany Hillard, MD
White Plains Hospital
Charles Noyer, MD
White Plains Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”